The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses
Open accessAbstract
BACKGROUND: Candidate human papillomavirus (HPV) vaccines have demonstrated almost 90%-100% efficacy in preventing persistent, type-specific HPV infection over 18 mo in clinical trials. If these vaccines go on to demonstrate prevention of precancerous lesions in phase III clinical trials, they will be licensed for public use in the near future. How these vaccines will be used in countries with national cervical cancer screening programmes is an important question. METHODS AND FINDINGS: We developed a transmission model of HPV 16 infection and progression to cervical cancer and calibrated it to Finnish HPV 16 seroprevalence over time. The model was used to estimate the transmission probability of the virus, to look at the effect of changes in patterns of sexual behaviour and smoking on age-specific trends in cancer incidence, and to explore the impact of HPV 16 vaccination. We estimated a high per-partnership transmission probability of HPV 16, of 0.6. The modelling analyses showed that changes in sexual behaviour and smoking accounted, in part, for the increase seen in cervical cancer incidence in 35- to 39-y-old women from 1990 to 1999. At both low (10% in opportunistic immunisation) and high (90% in a national immunisation programme) coverage of the adolescent population, vaccinating women and men had little benefit over vaccinating women alone. We estimate that vaccinating 90% of young women before sexual debut has the potential to decrease HPV type-specific (e.g., type 16) cervical cancer incidence by 91%. If older women are more likely to have persistent infections and progress to cancer, then vaccination with a duration of protection of less than 15 y could result in an older susceptible cohort and no decrease in cancer incidence. While vaccination has the potential to significantly reduce type-specific cancer incidence, its combination with screening further improves cancer prevention. CONCLUSIONS: HPV vaccination has the potential to significantly decrease HPV type-specific cervical cancer incidence. High vaccine coverage of women alone, sustained over many decades, with a long duration of vaccine-conferred protection, would have the greatest impact on type-specific cancer incidence. This level of coverage could be achieved through national coordinated programmes, with surveillance to detect cancers caused by nonvaccine oncogenic HPV types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Natural History of Cervicovaginal Papillomavirus Infection in Young Women
Ho, G. Y. F., Bierman, R., Beardsley, L., Chang, C. J., & Burk, R. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380703 · Cited by 2,329
NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN
Loria, G. R., Ierman, R. O. B., Eardsley, L. E. B., & Hang, H. J. C. (1998) · Cited by 1,890
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Self-citationHuman papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600688 · Cited by 1,561
Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis
Hausen, H. Z. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.690 · Cited by 1,298
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
The cervical cancer epidemic that screening has prevented in the UK
Peto, J., Gilham, C., Fletcher, O., & Matthews, F. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16674-9 · Cited by 808
Lăără, E., Day, N., & Hakama, M. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92695-x · Cited by 657
Castellsague, X., & Munoz, N. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003477 · Cited by 606
Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N., & Galloway, D. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315498 · Cited by 575
Sexual Attitudes and Lifestyles
Ashton, J. (1994) · Journal of Epidemiology and Community Health · doi:10.1136/jech.48.5.527-a · Cited by 563
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Measuring sexual behaviour: methodological challenges in survey research
Fenton, K. A. (2001) · Sexually Transmitted Infections · doi:10.1136/sti.77.2.84 · Cited by 531
Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L., & Matchar, D. B. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010166 · Cited by 470
Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.
(2001) · Europe PMC (PubMed Central) · Cited by 463
MANHART, L. E., & KOUTSKY, L. A. (2002) · Sexually Transmitted Diseases · doi:10.1097/00007435-200211000-00018 · Cited by 381
Evaluating Human Papillomavirus Vaccination Programs
Taira, A. V., Neukermans, C. P., & Sanders, G. D. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1011.040222 · Cited by 379
PHAGOCYTOSIS IN CHRONIC GRANULOMATOUS DISEASE
De Gast, G. C., Ydema, W., Wiersma, M., & Dankert, J. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92245-x · Cited by 361
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam, S. L. (2003) · JAMA · doi:10.1001/jama.290.6.781 · Cited by 337
Carter, J. J., Koutsky, L. A., Wipf, G. C., Christensen, N. D., Lee, S.-K., Kuypers, J., Kiviat, N., & Galloway, D. A. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.5.927 · Cited by 326
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Sanders, G. D., & Taira, A. V. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0901.020168 · Cited by 310
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., Decarvalho, N. S., et al. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000154423.27940.68 · Cited by 247
Role of Herd Immunity in Determining the Effect of Vaccines against Sexually Transmitted Disease
Garnett, G. P. (2005) · The Journal of Infectious Diseases · doi:10.1086/425271 · Cited by 244
Self-citationPapillomavirus Infections in Human Pathology
Syrjanen, K. J., & Syrjänen, S. (2000) · Medical Entomology and Zoology · Cited by 238
The serological response to papillomaviruses
Dillner, J. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0146 · Cited by 231
The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine
Hughes, J. P., Garnett, G. P., & Koutsky, L. (2002) · Epidemiology · doi:10.1097/00001648-200211000-00006 · Cited by 230
Self-citationAnttila, A., Pukkala, E., S�derman, B., Kallio, M., Nieminen, P., & Hakama, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<59::aid-ijc12>3.0.co;2-n · Cited by 197
Determining Transition Probabilities: Confusion and Suggestions
Miller, D. K., & Homan, S. M. (1994) · Medical Decision Making · doi:10.1177/0272989x9401400107 · Cited by 197
Human Papillomaviruses and Cervical Neoplasia: A Model for Carcinogenesis
Stoler, M. H. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200001000-00004 · Cited by 194
Sexual Attitudes and Lifestyles
Jones, M. (1994) · Sexually Transmitted Infections · doi:10.1136/sti.70.5.364 · Cited by 189
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
Carter, J. J., Madeleine, M. M., Shera, K. A., Schwartz, S. M., Cushing‐Haugen, K. L., Wipf, G. C., Porter, P. L., Daling, J. R., McDougall, J. K., & Galloway, D. A. (2001) · PubMed · Cited by 182
Estimating number of lifetime sexual partners: Men and women do it differently
Brown, N. R., & Sinclair, R. C. (1999) · The Journal of Sex Research · doi:10.1080/00224499909551999 · Cited by 169
Dillner, J., Kallings, I., Brihmer, C., Sikstrom, B., Koskela, P., Lehtinen, M., Schiller, J. T., Sapp, M., & Mardh, P. A. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/173.6.1394 · Cited by 165
Self-citationAn introduction to mathematical models in sexually transmitted disease epidemiology
Garnett, G. P. (2002) · Sexually Transmitted Infections · doi:10.1136/sti.78.1.7 · Cited by 163
Self-citationHuman papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Stability over Time of Serum Antibody Levels to Human Papillomavirus Type 16
af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P. U., la, E. P., Schiller, J. T., Lehtinen, M., & Dillner, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/517428 · Cited by 139
Self-citationvan Ballegooijen, M., Marle, M. E. V. D. A., Patnick, J., Lynge, E., Arbyn, M., Anttila, A., Ronco, G., Dik, J.-W. H., & Habbema, F. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00330-0 · Cited by 118
Modeling Age- and Time-Specific Incidence from Seroprevalence: Toxoplasmosis
Ades, A. E., & Nokes, D. J. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116758 · Cited by 103
Laukkanen, P., Koskela, P., Pukkala, E., Dillner, J., Läärä, E., Knekt, P., & Lehtinen, M. (2003) · Journal of General Virology · doi:10.1099/vir.0.18995-0 · Cited by 99
Self-citationKjellberg, L., Wang, Z., Wiklund, F. E., Edlund, K., Angstr√∂m, T., Lenner, P., Sj√∂berg, I., Hallmans, G., Wallin, K., Sapp, M. J., et al. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-2-391 · Cited by 96
Advances in the Diagnosis and Treatment of Human Papillomavirus Infections
Sedlacek, T. V. (1999) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-199906000-00006 · Cited by 61
Sigstad, E., Lie, A. K., Luostarinen, T., Dillner, J., Jellum, E., Lehtinen, M., Thoresen, S., & Abeler, V. M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600454 · Cited by 36
Self-citationGarnett, G. P., & Gregson, S. (2000) · Mathematical Population Studies · doi:10.1080/08898480009525485 · Cited by 25
Self-citation
Cited by
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
Forouzanfar, M. H., Foreman, K. J., Delossantos, A. M., Lozano, R., Lopez, A. D., Murray, C. J. L., & Naghavi, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61351-2 · Cited by 1,009
Human Papillomavirus Testing in the Prevention of Cervical Cancer
Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., & Castle, P. E. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq562 · Cited by 759
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States
Chesson, H. W., Dunne, E. F., Hariri, S., & Markowitz, L. E. (2014) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000193 · Cited by 706
Metadata
- Authors
- Barnabas, R. V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M., & Garnett, G. P.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-04-04
- Volume
- 3
- Issue
- 5
- Pages
- e138
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2132338556
- Cited by
- 293
- References
- 46
- FWCI
- 25.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.